Zacks Investment Research upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a report released on Friday, January 12th. The firm currently has $26.00 price target on the medical equipment provider’s stock.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
A number of other research analysts have also recently commented on LNTH. Jefferies Group reiterated a buy rating and set a $22.00 price target on shares of Lantheus in a research report on Thursday, October 12th. Wells Fargo & Co upgraded shares of Lantheus from a market perform rating to an outperform rating in a research report on Thursday, November 2nd. Credit Suisse Group increased their price target on shares of Lantheus from $19.00 to $23.00 and gave the company a neutral rating in a research report on Friday, November 3rd. ValuEngine cut shares of Lantheus from a buy rating to a hold rating in a report on Friday, December 1st. Finally, BidaskClub cut shares of Lantheus from a strong-buy rating to a buy rating in a report on Tuesday, December 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $24.75.
Shares of Lantheus (LNTH) traded up $0.20 during midday trading on Friday, reaching $22.10. 34,501 shares of the company’s stock were exchanged, compared to its average volume of 284,744. Lantheus has a twelve month low of $8.50 and a twelve month high of $24.45. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. The company has a market capitalization of $821.38, a PE ratio of 27.04, a P/E/G ratio of 1.42 and a beta of 0.95.
In related news, insider Michael P. Duffy sold 21,655 shares of the firm’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $22.40, for a total value of $485,072.00. Following the completion of the sale, the insider now owns 156,784 shares of the company’s stock, valued at $3,511,961.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John W. Crowley sold 3,866 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $23.52, for a total value of $90,928.32. The disclosure for this sale can be found here. Insiders sold 48,752 shares of company stock valued at $1,077,129 in the last ninety days. 2.30% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in LNTH. Schwab Charles Investment Management Inc. purchased a new position in Lantheus during the second quarter valued at $770,000. First Trust Advisors LP lifted its position in Lantheus by 24.8% during the second quarter. First Trust Advisors LP now owns 23,468 shares of the medical equipment provider’s stock valued at $414,000 after buying an additional 4,669 shares during the period. Rhumbline Advisers purchased a new position in Lantheus during the second quarter valued at $903,000. Bank of New York Mellon Corp lifted its position in Lantheus by 434.6% during the second quarter. Bank of New York Mellon Corp now owns 366,048 shares of the medical equipment provider’s stock valued at $6,460,000 after buying an additional 297,575 shares during the period. Finally, Legal & General Group Plc bought a new position in shares of Lantheus during the second quarter valued at $908,000. 91.07% of the stock is owned by institutional investors and hedge funds.
WARNING: “Lantheus (LNTH) Upgraded to Buy by Zacks Investment Research” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/05/lantheus-lnth-upgraded-to-buy-at-zacks-investment-research.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Get a free copy of the Zacks research report on Lantheus (LNTH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.